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Abstract
Malignant melanoma is one of the most aggressive human cancers, but the mechanisms governing its
metastatic dissemination are not fully understood. Upregulation of miR-214 and ALCAM and the loss of
TFAP2 expression have been implicated in this process, with TFAP2 a direct target of miR-214. Here, we link
miR-214 and ALCAM as well as identify a core role for miR-214 in organizing melanoma metastasis. miR-
214 upregulated ALCAM, acting transcriptionally through TFAP2 and also posttranscriptionally through
miR-148b (itself controlled by TFAP2), both negative regulators of ALCAM. We also identified several miR-
214–mediated prometastatic functions directly promoted by ALCAM. Silencing ALCAM in miR-214–over-
expressing melanoma cells reduced cell migration and invasion without affecting growth or anoikis in vitro,
and it also impaired extravasation and metastasis formation in vivo. Conversely, cell migration and
extravasation was reduced in miR-214–overexpressing cells by upregulation of either miR-148b or TFAP2.
These findings were consistent with patterns of expression of miR-214, ALCAM, and miR-148b in human
melanoma specimens. Overall, our results define a pathway involving miR-214, miR-148b, TFAP2, and
ALCAM that is critical for establishing distant metastases in melanoma. Cancer Res; 73(13); 4098–111. 2013
AACR.
Introduction
Malignant melanoma represents the fifth most common
neoplasia in human and is one of the most invasive, therapy-
resistant, and metastatic tumors, with only about 10%
survival, 5 years after diagnosis (1). Over the past decades,
its incidence has been increasing by 3% to 8% per year in
Western countries while mortality has stabilized. Therefore,
it is essential to unravel the molecular events that regulate
melanoma aggressiveness and metastatic dissemination.
Melanoma progresses rapidly through a radial growth phase,
confined entirely in the epidermis, followed by a subsequent
vertical growth phase, corresponding to the high-risk mel-
anomas, characterized by invasion of the epidermis upper
layer, deep infiltration of the dermis and subcutaneous
tissues and formation of lymph-nodal, cutaneous, and vis-
ceral metastases in a vast majority of cases (2, 3). The
transition from the noninvasive to the invasive and meta-
static stage is accompanied by specific and well-character-
ized molecular changes, such as loss of the AP-2 transcrip-
tion factors (TFAP2) and expression alterations for genes
involved in adhesion, angiogenesis, invasion, and survival,
including MCAM-MUC-18, ALCAM, E-cadherin, N-cadherin,
VEGF, interleukin (IL)-8, matrix metalloproteinase (MMP)-2,
and c-KIT (3). Moreover, BRAFV600E oncogenic mutation is
one of the earliest and common molecular events that
characterize malignant melanoma (2).
The activated leukocyte cell adhesion molecule, ALCAM/
CD166, is a transmembrane glycoprotein, member of the
immunoglobulin superfamily, involved in both homotypic and
heterotypic (to CD6) cell adhesion (4). ALCAM cis-oligomer-
ization on the cell surface and intercellular interactions
synergistically promote network formation at site of cell–cell
contacts (5, 6). ALCAM expression is altered in many types of
tumors, including melanomas, where it is considered as a
prognostic molecular marker for neoplastic progression (7).
Indeed, while ALCAM expression is low or absent in nevi, in
situ, and thin melanomas, ALCAM is detectable in the vertical
growth phase melanomas and in metastatic lesions. Signifi-
cantly, the fraction of ALCAM-positive lesions increases
according to invasiveness (Clark level) and thickness (Breslow
index) of the melanocytic tumor (8). It was shown that any
interference with ALCAM function affects melanoma cell
movement and invasion (9, 10) and that ALCAM triggers
MMP2 and MMP14 activity (11). However, it is still not known
howALCAMoverexpression is induced inmelanomas and how
it coordinates metastasis formation.
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miRNAs (miR) are small endogenous noncoding RNAs that
deeply contribute to tumor formation and progression, for
their ability to posttranscriptionally downregulate the expres-
sion of specific target genes by binding to the 30-untranslated
regions (UTR) of their mRNAs, causing degradation or trans-
lation inhibition (12–15). Several miRs, including miR-137,
miR-221/222, miR-182, and miR-34a have been found to be
involved in melanoma progression by regulating key genes
such asKIT,MITF, FOXO3, ITGB3,CCND1, andCDKN1B (16). By
using a melanoma progression model (17), consisting of a
poorly metastatic human melanoma A375P parental cell line
and its highly metastatic variants (MA-2, MC-1), we recently
showed that miR-214 coordinates melanoma metastasis dis-
semination by increasing migration, invasion, extravasation,
and survival of melanoma cells. In addition, we identified a
pathway coordinated by miR-214 and involving TFAP2A and
TFAP2C as well as multiple adhesion molecules, including
ALCAM (18). Here, we show that miR-214 mediates ALCAM
upregulation by silencing TFAP2 and miR-148b, both negative
regulators of ALCAM. More importantly, we present evidences
that some miR-214–mediated prometastatic functions are
directly exerted by ALCAM.
Materials and Methods
Cell culture
A375P, MA-2, and MC-1 cells were provided by R.O. Hynes
(Massachusetts Institute of Technology, Cambridge, MA) and
maintained as described previously (17, 18). WK-Mel, SK-Mel-
28, and human umbilical vein endothelial cells (HUVEC)-GFP
were provided by P. Circosta (Molecular Biotechnology Center,
Torino, Italy), L. Poliseno (Core Research Laboratory - Istituto
Toscano Tumori, CRL-ITT, Pisa, Italy), and L. Primo (Institute
for Cancer Research and Treatment, Candiolo, Italy), respec-
tively andmaintained as described (19–21).MDA-MB-231were
from American Type Culture Collection. All the cell lines used
were authenticated in the last 6 months by BMR Genomics
using the CELL ID System (Promega). BRAFV600Emutation was
previously described (21) or assessed by sequencing and
pyrosequencing analyses as described in ref. 22. Transient
transfections and generation of stable cell lines by lentiviral
infections were conducted as described previously (18).
Reagents, antibodies, vectors, primers, RNA, protein,
and human melanoma samples analyses
pLemiR-empty and pLemiR-214 expression vectors were
described in ref. 18. siALCAM#1 and #2 target 2 different
regions within ALCAM coding sequence (starting at positions
1350 and 2123 of ALCAM gene, respectively) and were pur-
chased from QIAGEN (Hs_ALCAM_5 and Hs_ALCAM_6 High
Purity-validated siRNAs). pLKO.1-shALCAM lentiviral vector
targets a region within ALCAM 30-UTR (at position 2624 of
ALCAM gene) and was purchased from Open Biosystems (cat.
no. RHS3979). miR precursors and inhibitors and assays for
quantitative real-time PCR (qRT-PCR) miR detection were
from Applied Biosystems. RNA (miR and mRNA) and protein
extraction and detection (qRT-PCR and Western blotting,
respectively) were previously described in ref. 18. Luciferase
and chromatin immunoprecipitation (ChIP) assays were con-
ducted with the Dual-Luciferase Reporter System (Promega)
and the EZ-Magna ChIP G (Millipore) kits, respectively. Mel-
anoma samples were collected from the Institute Dermato-
logic Clinic of the University of Torino (Torino, Italy) and
approvals were obtained for all samples; RNA extraction and
analyses were conducted as in ref. 18.
In vitro biologic assays
Migration, invasion, proliferation, anchorage-independent
growth, transendothelial migration, and anoikis assays were
previously described in ref. 18.
In vivo metastasis assays
All experiments carried out with live animals complied
with ethical animal care. For experimental metastasis assays,
5 105 MA-2, WK-Mel, and SK-Mel-28 cells were injected into
the tail vein of 6- to 8-week-old NOD/SCID/IL2Rgnull (NSG)
immunocompromised mice and the animals were dissected 3
(MA-2, SK-Mel-28) or 5 (WK-Mel) weeks later. Spontaneous
metastases were evaluated in 6- to 8-week-old NSG mice
subcutaneously injected in the back with 5  106 MA-2 cells
and dissected 7 weeks later. Red fluorescent lung and liver
(when present) metastases were evaluated and photographed
in fresh total lungs using a Leica MZ16F fluorescence stereo-
microscope. The area or the number of metastases was mea-
sured on photographs using the ImageJ software (http://
rsbweb.nih.gov/ij/). Micrometastases were evaluated with the
Panoramic View program on paraffin-embedded and hema-
toxylin and eosin (H&E)–stained specimens, scanned with
Panoramic Desk (3DHistech; Euroclone).
In vivo extravasation assay
A total of 1.5 106MA-2 orWK-Mel cells, previously labeled
with CellTracker Orange CMRA (Molecular Probes, Invitrogen
Life Technologies), were injected into the tail vein of 7-week-
old female CD1 nudemice (Charles River Laboratories). Two or
48 hours later, mice were sacrificed and 4% paraformaldeyde
was injected into the trachea. Total lungs were dissected and
photographed using a Leica MZ16F fluorescence stereomicro-
scope and red fluorescent cells were counted 48 hours follow-
ing injections using the ImageJ software (http://rsbweb.nih.
gov/ij/). Lungs were included in freezing resin (OCTKillik, Bio-
Optica, IT) and cryostat-cut in 6-mm thick sections. Immuno-
fluorescent stainings for blood vessels were conducted with
anti-CD31 primary antibody (1:100 dilution) and specimens
examined using a Zeiss AxioObserver microscope with the
ApoTome Module (18).
In silico analyses
TFAP2 putative binding sites were obtained by the classical
positional weight matrices (PWM) approach (23), as described
in ref. 24. TFAP2 matrix was obtained from the JASPAR CORE
database and background nucleotide frequencies were derived
from the analyzed sequence. We considered high-affinity sites
those with a score higher than 80% of the maximum score (i.e.,
the score of the perfect match for the PWM) and low-affinity
sites those less than 80% but more than 60%. To assess direct
interactions between miR-214 and miR-148b, we evaluated
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2,000 nucleotides upstream and downstream of pre-miR-148b,
considering the mean lengths of pri-miRs reported in ref. 25.
RNAHybrid algorithm (26) was used, either with orwithout the
option that forces to obtain a perfect helix in the 2 to 7 region of
the seed. The P valuewas estimated using as background either
the human intronic dinucleotides frequencies or the default 30-
UTR–based ones. P > 0.05 was considered nonstatistically
significant. The result was confirmed by LALIGN manual
alignment program.
Statistical analyses
Data are presented as mean  SD or as mean  SEM, as
indicated, and two-tailed Student t test was used for compar-
ison, with , P < 0.05; , P < 0.01; , P < 0.001 considered to be
statistically significant. ns indicates a nonstatistically signifi-
cant P value.
All reagents, antibodies, vectors, and primer sequences used
in this study, as well as detailed experimental procedures are
described in the Supplementary Materials and Methods.
Results
ALCAM is upregulated by miR-214 in melanoma
As summarized in Supplementary Table S1, here and pre-
viously (18), we proved that the ability of miR-214 to promote
cell movement and metastasis formation in vitro is indepen-
dent of BRAFV600E mutation status as for various melanoma
cell lines analyzed. Interestingly, when miR-214 was overex-
pressed both in a transient (pre-miR-214, 48 and 72 hours
posttransfection) or stable (pLemiR-214) manner in the
BRAFV600E-mutated A375P, MA-2, and SK-Mel-28 or in the
BRAFWTWK-Melmelanoma cell lines (Supplementary Fig. S1A
and S1B), a significant ALCAM protein or mRNA upregulation
Figure 1. ALCAM is upregulated by miR-214 and controls melanoma cell movement. A and B, Western blot analyses of ALCAM protein levels in the indicated
melanoma cell lines after transfections with miR-214 precursors or inhibitors or their negative controls (pre- and anti-miR-214 or -control, 72 or
48 hours posttransfection, respectively) or in MA-2 cells stably transduced with pLemiR-empty or miR-214 overexpression (pLemiR-214) vectors. Protein
modulations were calculated relative to controls, normalized on tubulin or hsp90 or GAPDH loading controls, and expressed as percentages. C and D,
ALCAM mRNA levels measured by qRT-PCR in the indicated melanoma cells transfected or transduced as in A and B. Results were calculated as fold
changes (mean  SD of triplicates) relative to controls, normalized on 18S RNA level. E–L, Transwell migration (E–K) or Matrigel invasion (L) assays
for MA-2, WK-Mel or SK-Mel-28 cells transiently transfected with either pLVX-empty or pLVX-ALCAM overexpression vectors (E), or with either control or
ALCAM-targeting siRNAs (si-control or si-ALCAM#1 or #2; F–H), or cotransduced with pLemiR-empty or pLemiR-214 vectors and with either empty or
ALCAM-targeting shRNA vectors (pLKO-empty or pLKO-shALCAM; I–L). Results are shown as mean  SEM of the area covered by migrated cells. At least
2 independent experiments were carried out (in triplicate for C–L) and representative results are shown.
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(fromþ35% toþ280%) was observed as shown inWestern blot
(Fig. 1A and Supplementary Fig. S2A) or qRT-PCR (Fig. 1C)
analyses, compared with controls (pre-control or pLemiR-
empty), independently of BRAF alterations. Consistently, as
shown in Fig. 1B and D, ALCAM expression was decreased
(60%) both at protein and at mRNA level following miR-214
inhibition by anti-miR-214 in transiently transfectedMC-1 cells
(Supplementary Fig. S1E) compared with controls. Reduced
ALCAM expression was also observed in cells expressing miR-
214–specific sponges (Orso and colleagues, unpublished data).
Relevantly, correlation between miR-214 overexpression and
ALCAM upregulation was also observed in other tumor cells,
such as the breast cancer MDA-MB-231 cells (Supplementary
Figs. S1A and S2A).
ALCAM upregulation controls miR-214–mediated
melanoma cell movement, invasion, and metastatic
dissemination
To investigate the potential involvement of ALCAM in miR-
214 prometastatic functions, we first modulated ALCAM in
different melanoma cells to obtain transient overexpression or
silencing, using respectively a cDNA-expression vector (pLVX-
ALCAM, MA-2 cells) or 2 independent siRNAs (si-ALCAM#1
and #2, MA-2 and SK-Mel-28 cells) and evaluated its biologic
relevance compared with control cells (pLVX-empty or si-
control, respectively). As shown by Western blot analyses in
Supplementary Fig. S1I, relevant ALCAM upregulation or
silencing was obtained. These cells were used to evaluate cell
growth and migration in vitro and, while no effects were
observed for serum-dependent proliferation (Supplementary
Fig. S2B), a significant enhancement or reduction of cell
movement was observed for ALCAM overexpressing (Fig.
1E) or silenced (Fig. 1F and G) cells, compared with controls,
thus phenocopying miR-214 expression modulations (18). To
assess whether the prometastatic phenotype associated with
miR-214 overexpression inmelanoma cells could be rescued, at
least in part, by ALCAM silencing, we silenced ALCAM in a
transient manner by siRNAs (Fig. 1H; WK-Mel cells) or stably
(pLKO-shALCAM) in control (pLemiR-empty) or miR-214–
overexpressing (pLemiR-214) MA-2, WK-Mel, and SK-Mel-28
cells, compared with controls (si-control or pLKO-empty), as
shown in Supplementary Fig. S1I. When we evaluated the
biologic properties of these cells in vitro, we observed a strong
reduction (about 50% decrease) in cell migration or Matrigel
invasion following ALCAM silencing in miR-214–overexpres-
sing cells (Fig. 1H–L), whereas no effect on MA-2 serum-
dependent proliferation (Supplementary Fig. S2C) or anchor-
age-independent growth in soft agar (Supplementary Fig. S2D)
was found, leading us to conclude that ALCAM is able to rescue
miR-214–induced increase in cell movement.
As previously shown for MA-2 cells (18) and in Fig. 2B and C
for WK-Mel and SK-Mel-28 cells, miR-214 overexpression
(pLemiR-214) induces increased metastatic dissemination in
vivo, compared with empty controls. To evaluate the role of
ALCAM in miR-214–mediated melanoma cell dissemination,
miR-214–overexpressingMA-2 (Fig. 2A) orWK-Mel (Fig. 2B) or
miR-214–overexpressing SK-Mel-28 (Fig. 2C) cells (pLemiR-
empty or pLemiR-214, turbo red fluorescent protein-tRFP–
positive), stably silenced (pLKO-shALCAM) or not (pLKO-
empty) for ALCAM, were injected in the tail vein of severely
immunocompromised NSGmice and metastatic nodules eval-
uated 3 to 5 weeks postinjections in the lungs (and livers for
MA-2 cells). As assessed by the quantitation ofmetastatic areas
in the whole organs (Fig. 2A, a–d) or in H&E-stained sections
(Supplementary Fig. S2F, a and b), or by counting metastatic
colonies in H&E-stained sections (Fig. 2B, a–d) or in whole
lungs (Fig. 2C, a–e), colony formation for ALCAM-silenced
melanoma cells was significantly impaired compared with
controls and, more importantly, ALCAM silencing in miR-
214–overexpressing cells rescued miR-214–driven increased
metastasis formation. In addition, spontaneous metastasis
formation was evaluated following subcutaneous injection of
miR-214–overexpressing ALCAM-silenced MA-2 cells in NSG
mice, looking for fluorescent microscopic metastatic lesions 7
weeks later. Primary tumor growthwas also evaluated here and
no difference was found (Fig. 2D, top). However, as shown
in Fig. 2D, bottom, a–c, the increased number of lung micro-
metastases found for miR-214–overexpressing cells was sig-
nificantly rescued when ALCAM was silenced. Very few met-
astatic lesions were observed in the livers.
Because these in vitro and in vivo results were obtained for 3
distinct melanoma cell lines and independently of BRAFV600E
mutation status (Supplementary Table S1), they indicate a
general key role for miR-214–mediated ALCAM upregulation
in melanoma metastasis. Interestingly, transient ALCAM
silencing (si-ALCAM#1) was able to significantly reduce in
vitro cellmovement comparedwith si-control also in theMDA-
MB-231 breast cancer cell line (Supplementary Figs. S1I and
S2E), suggesting a broader function for miR-214–driven
ALCAM upregulation in tumor cell movement.
ALCAM controls melanoma cell extravasation
To evaluate the possible involvement of ALCAM in tumor
cell extravasation, we first analyzed in vitro transendothelial
migration by seeding CMRA-labeled (red) MA-2 cells previ-
ously silenced (si-ALCAM#1) or not (si-control) for ALCAM
in the upper chamber of Transwell covered by a confluent
HUVECs-GFP monolayer. As shown in Fig. 3A, ALCAM down-
modulation (b) decreased transendothelial migration com-
pared with control (a). More relevantly, ALCAM transient
(si-ALCAM#1; Supplementary Fig. S2G) or stable (pLKO-
shALCAM) downmodulation in miR-214–overexpressing MA-
2 cells (pLemiR-214, tRFP-positive) abolished miR-214–medi-
ated enhancement of transendothelial migration (pLemiR-
214þpLKO-empty) and reestablished migration levels compa-
rable with controls (pLemiR-emptyþpLKO-empty; Fig. 3B, a–
c). Transient ALCAM silencing was able to significantly reduce
transendothelial migration also in MDA-MB-231 cells (Supple-
mentary Fig. S2H), again suggesting a general role in tumor
cell dissemination. We then evaluated ALCAM involvement in
in vivo extravasation in the lungs of immunocompromised
mice following tail vein injections of miR-214–overexpressing
MA-2 or WK-Mel cells (pLemiR-214) transduced with either
pLKO-shALCAM or pLKO-empty control (Fig. 3C and D). The
lodging in lung vasculature was evaluated 2 hours post-
injection (a and b) when the cells resulted localized inside or
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associated with blood vessels, as shown by vessel stainings
(Supplementary Fig S2I, a and b), and no difference was
observed. Instead, a 50% decrease in early lung colonization
at 48 hours postinjectionwas found followingALCAMsilencing
compared with controls (c and d). At this time point,
the melanoma cells were extravasated and dispersed in the
lung parenchyma (Supplementary Fig S2I, c and d). When we
tested the possible ALCAM function in cell survival in the
absence of adhesion and serum (anoikis), that is a condition
resembling the situation of detached invading or intravasated
tumor cells, only an irrelevant increase of apoptosis for
ALCAM-silenced MA-2 cells (pLKO-shALCAM, Fig. 3E) was
observed.
miR-214–driven ALCAMupregulation inmelanoma cells
partially depends on TFAP2-mediated transcriptional
repression
To identify the molecular mechanisms leading to ALCAM
upregulation by miR-214, we first considered a possible tran-
scriptional regulation. We previously showed that the tran-
scription factors TFAP2A and TFAP2C are targeted bymiR-214
in MA-2 cells (18); we now observed relevant TFAP2A and
TFAP2C downmodulation by miR-214 also inWK-Mel and SK-
Mel-28 cells (Fig 4A). Thus, we evaluated the possibility of a
TFAP2-mediated transcriptional repression on the ALCAM
promoter. To test the potential ALCAM transcriptional repres-
sion by TFAP2 factors, MA-2 cells were transiently transfected
Figure 2. ALCAMupregulation bymiR-214promotesmelanomametastasis formation. A–C, colony formation in lungs (A, left; B andC) or livers (A, right) ofNSG
mice, 3 or 5 weeks after tail vein injection of MA-2, WK-Mel, or SK-Mel-28 cells, transduced or cotransduced with pLemiR-empty or miR-214 overexpression
(pLemiR-214) vectors (expressing tRFP) and/or with either empty or ALCAM-targeting shRNA vectors (pLKO-empty or pLKO-shALCAM). D, NSG
mice were subcutaneously injected in the back with MA-2 cells cotransduced with pLemiR-empty or pLemiR-214 vectors (expressing tRFP) and with either
pLKO-empty or pLKO-shALCAM vectors and sacrificed 7 weeks later. Primary tumor weights are shown at the top, lung micrometastases at the
bottom. Representative pictures of whole lungs and livers (A, a–d, bar, 2 mm; C, a–e; and D, a–c, bar, 800 mm) or of H&E stainings (B, a–d, bar, 200 mm) are
shown. Results are indicated as mean  SEM of the fluorescent area (A) or of the number of lung colonies counted on H&E-stained sections (B) or
of the number offluorescent colonies counted in thewhole lungs (CandD,bottom) or asboxandwhiskersplot for tumorweights (D, top) for the number ofmice
per group (n) indicated in each column. Two independent experiments were carried out for A and B and representative results are shown.
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with TFAP2A or TFAP2C expression constructs [pSP(RSV)-
TFAP2A, pSP(RSV)-TFAP2C], or with the combination of both,
or with an empty control [pSP(RSV)-empty] and ALCAM
mRNA and protein expression was analyzed by qRT-PCR and
Western blot analysis, respectively. As shown in Fig. 4B and C,
TFAP2 overexpression resulted in 20% to 40% decreased
ALCAM mRNA and protein expression, 48 and 72 hours post-
transfection, respectively. A similar ALCAM protein down-
modulation following TFAP2 overexpression was observed in
WK-Mel cells (Fig. 4D). Consistently, in TFAP2C-silenced cells
(pLKO-shTFAP2C), we observed 20% increased ALCAM pro-
tein expression compared with control (pLKO-empty), as
shown in Fig. 4E. These results suggested that miR-214–driven
ALCAM upregulation could depend on TFAP2A and/or
TFAP2C decrease due to miR-214 targeting. In line with this,
we observed lower ALCAM levels in miR-214–overexpressing
(pLemiR-214) MA-2 cells when TFAP2A or, to a lesser extent,
TFAP2C [pSP(RSV)-TFAP2A, pSP(RSV)-TFAP2C] or both were
overexpressed compared with controls (Fig. 4F). The ALCAM
promoter region, from 900 to þ100 bp relative to the
Figure 3. ALCAM controls
melanoma cell extravasation.
A andB, transendothelial migration
assays of CMRA-labeled MA-2
cells transiently transfected with
either control or ALCAM-targeting
siRNAs (si-control or si-ALCAM#1;
A) or of MA-2 cells cotransduced
with pLemiR-empty or miR-214
overexpression (pLemiR-214)
vectors (expressing tRFP) and with
either empty or ALCAM-targeting
shRNA vectors (pLKO-empty or
pLKO-shALCAM; B), through a
fibronectin-coated Transwell
membrane covered by a confluent
monolayer of HUVECs-GFP.
Transmigrated MA-2 cells on the
lower side of the Transwell are
shown in a–c. Bar, 50 mm. C and D,
in vivo extravasation assays 2
hours (a and b) or 48 hours (c and d)
following tail vein injections in nude
mice of MA-2 (C) or WK-Mel (D)
cells cotransduced as in B.
Representative pictures of whole
lungs are shown; bar, 800 mm.
E, anoikis assay for MA-2 cells
transducedas inCandplated in the
absence of adhesion and serum for
72 hours. Cell death percentage
was evaluated by Annexin
V–allophycocyanin staining,
displayed in bidimensional plots.
Left quadrant, healthy population;
right quadrant, apoptotic
population. Two or 3 independent
experiments were carried out (in
triplicate for A, B, and E) and
representative results are shownas
mean  SEM of the area covered
bymigrated cells (A and B) or of the
number of extravasated cells
at 48 hours for n¼ 5mice per group
(C and D) or as percentages of
cells (E).
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Figure 4. ALCAM is transcriptionally repressed by TFAP2 in melanoma. A–F, ALCAM, TFAP2A, and TFAP2C protein (A, C–F) or mRNA (B) expression levels
were analyzed respectively byWestern blot analysis andqRT-PCRat 48 (B) and72hours (A, C, D, andF) following transient transfection ofWK-Mel or SK-Mel-
28 with miR-214 precursors or negative controls (pre-miR-214 or -control; A), or of MA-2 or WK-Mel cells (B–D) or of miR-214–overexpressing MA-2 cells
(pLemiR-214, F) with pSP(RSV)-empty or TFAP2A or TFAP2C overexpression vectors [pSP(RSV)-TFAP2A or pSP(RSV)-TFAP2C] or the combination of both,
or in MA-2 cells stably transducedwith either empty or TFAP2C-targeting shRNA vectors (pLKO-empty or pLKO-shTFAP2C, E). In B, results were calculated
as fold changes (mean  SD of triplicates) relative to controls, normalized on 18S RNA level. In A and C–F, protein modulations were calculated relative to
controls, normalized on GAPDH or hsp90 loading controls and expressed as percentages. G, scheme showing human ALCAM gene promoter region,
spanning from900 toþ100 nucleotides around the TSS. Five putative TFAP2-binding sites (BS) are indicated by circles. The portion between753 andþ35
was cloned in pGL3-Basic luciferase reporter vector (pGL3-ALCAMprom; see I). H, ChIP.MA-2 cross-linked sheared chromatinwas immunoprecipitatedwith
either negative control (IgG) or anti-TFAP2 antibodies and the TFAP2-binding sites–containing region was PCR-amplified. TFAP2-binding enrichment was
calculated relative to IgG-negative control. I, luciferase assays 48 hours posttransfection in MA-2 cells cotransfected with pGL3-Basic reporter constructs
containing WT (pGL3-ALCAMprom) or all (del_all) or specific (del_5 to del_1 and del_3þ5, 2þ3, 2þ3þ5) TFAP2-binding site-deleted ALCAM promoter
sequence cloned upstream of the luciferase coding sequence, together with pSP(RSV)-empty or pSP(RSV)-TFAP2A or pSP(RSV)-TFAP2C expression
vectorsor the combination of both. Results are shownasmeanSDof Firefly luciferaseactivity relative to controls, normalized onRenilla luciferase andon the
activity measured for the empty pGL3-Basic vector in presence of TFAP2. Two or 3 independent experiments were carried out, in triplicate for B and I and
representative results are shown.
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transcription start site (TSS), was analyzedwith bioinformatics
tools, using the canonical TFAP2-binding site PWM consisting
of a 9 nucleotide long G/C-rich sequence, shared for TFAP2A
and TFAP2C. Five putative TFAP2-binding sites (BS) were
identified, with high-affinity binding scores, at positions
316 (BS5), 249 (BS4), 208 (BS3), 163 (BS2), and 126
(BS1; Fig. 4G). A ChIP experiment was carried out using
cross-linked MA-2 chromatin, with negative (immunoglobulin
G, IgG) or positive (RNA polymerase II, PolII) control or anti-
TFAP2 (recognizing both TFAP2A and TFAP2C) antibodies.
Importantly, by PCR-amplifying the region containing
the 5 TFAP2-binding sites, more than 4-fold TFAP2-binding
enrichment was observed on this region relative to
IgG-negative control (Fig. 4H). As a positive control PolII-
immunoprecipitated DNA was tested with a glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) promoter PCR assay
(Supplementary Fig. S3A). To test the direct effect of TFAP2
on ALCAM promoter, the activity of the promoter region
between 753 and þ35 relative to the TSS, was assayed in a
luciferase reporter vector (pGL3-ALCAMprom). MA-2 cells
were cotransfected with either pGL3-ALCAMprom or pGL3-
empty and TFAP2A and/or TFAP2C expression constructs or
empty control [pSP(RSV)-TFAP2A, pSP(RSV)-TFAP2C, or pSP
(RSV)-empty] and luciferase activity was evaluated 48 hours
(Fig. 4I) and 72 hours (Supplementary Fig. S3B) posttransfec-
tion. pGL3-ALCAMprom luciferase activity was normalized on
pGL3-empty activity in a condition of TFAP2 overexpression.
As a positive control, a luciferase construct containing the
known TFAP2A-responsive ESDN promoter region (24) was
used (Supplementary Fig. S3C). pGL3-ALCAMprom activity
was significantly decreased in presence of TFAP2A or TFAP2C
or both (60% to 40% reduction), compared with pSP(RSV)-
empty control, indicating a direct transcriptional repression of
TFAP2 on ALCAM promoter (Fig. 4I, left). The single deletions
of the 5 binding sites one-by-one (del_5 to del_1) were not able
to rescue the luciferase activity, whereaswhenwedeleted 2 or 3
binding sites in combinations (del_3þ5, del_2þ3, del_2þ3þ5)
or the entire promoter region included between 316 and
126 thus eliminating all the 5 binding sites (del_all), we were
able to abrogate the luciferase activity decrease in presence of
TFAP2 (Fig. 4I, right), indicating that the cooperation of the 5
sites is probably required for TFAP2 repression of ALCAM
transcription.
miR-214–driven miR-148b downregulation controls
ALCAM overexpression posttranscriptionally in
melanoma cells
In addition to TFAP2-mediated transcriptional regulation,
we considered possible posttranscriptional mechanisms
involving other miRs. Because miR-148b was predicted to
directly target ALCAM, according to TargetScan 5.2 algorithm
(27), we evaluated ALCAM expression following miR-148b
overexpression (pre-miR-148b; Supplementary Fig. S1C, S1G,
and S1H) compared with pre-control in MA-2, WK-Mel, and
SK-Mel-28 cells 72 hours posttransfection. Significantly, a 40%
to 80% ALCAM protein reduction was found in Western blot
analyses (Fig. 5A–C). To investigate the direct binding of miR-
148b on ALCAM, the first 605 bp of ALCAM 30-UTR (Fig. 5F),
containing miR-148b putative binding site (at position 272–
277), was cloned in the pMIR-REPORT reporter vector down-
stream of the luciferase coding sequence (ALCAM30-UTR).
miR-148b–binding site was also mutated (point mutations or
deletion; shown in Fig. 5F) to generatemutant ALCAM30-UTRs
(ALCAMmut and ALCAMdel). Luciferase activity of wild-type
(WT) or mutant vectors was evaluated in MA-2 cells in
presence or absence of miR-148b overexpression (pre-miR-
148b or -control). A significant decrease of luciferase activity
was observed for theWTbut not for themutants in presence of
miR-148b compared with controls, indicating the specific
regulation of miR-148b on ALCAM 30-UTR (Fig. 5G). As a
positive control, a miR-148b sensor construct containing 3
perfect bindings for miR-148b was used (Fig. 5G). Importantly,
when we analyzed miR-148b levels in miR-214–overexpressing
(pre-miR-214) MA-2, WK-Mel, SK-Mel-28, and MDA-MB-231
cells, a significant reduction ofmiR-148b expression was found
at 24, 48 (Supplementary Fig. S3D;MA-2), and 72 hours (Fig. 5H,
MA-2; Fig. 5K, SK-Mel-28; Supplementary Fig. S3E, WK-Mel;
Supplementary Fig. S3F, MDA-MB-231 cells) compared with
pre-control), as evaluated by qRT-PCR. A similar miR-148b
reduction was obtained in stable miR-214–overexpressing
(pLemiR-214) MA-2 (Fig. 5I) or WK-Mel (Fig. 5J) cells, com-
pared with empty control (pLemiR-empty). Consistently, miR-
148b expression levels were increased in presence of anti-miR-
214 in MC-1 cells, compared with anti-control–transfected
cells (Fig. 5L). Other unrelated miRs, for instance miR-31, were
not affected by miR-214 overexpression (Fig. 5M). These data
suggest a regulatory loop between miR-214 and miR-148b,
which can affect ALCAM expression. Indeed, the concomitant
overexpression of miR-148b and miR-214 (pre-miR-214þpre-
miR-148b transfection) inMA-2 cells (Supplementary Fig. S1C)
or the reexpression ofmiR-148b in stablemiR-214–overexpres-
sing cells (pLemiR-214þpre-miR-148b; Supplementary Fig.
S1D) led to reduced ALCAMprotein (Fig. 5A and D) andmRNA
(Fig. 5E) levels, similar to control cells (pre-control or pLemiR-
emptyþpre-control, respectively).
miR-148b downregulation by miR-214 is partially due to
TFAP2 control
To explore how miR-214 downregulates miR-148b, we con-
ducted a bioinformatics analysis for miR-148b containing
human genomic locus (2,000 nucleotides upstream and down-
stream of pre-miR-148b), inside the intron 1 of COPZ1 protein-
coding gene. First, as described in ref. 28, we used RNA Hybrid
algorithm (26) to look for in silico evidences of a direct
interaction between miR-214 and miR-148b transcript, poten-
tially involved in controlling processing or stability. A single
putative 20-nucleotide long miR-214–binding site was found
650 nucleotides downstreamof the pre-miR-148b locus (Fig. 6A
and B), but with a nonstatistically significant (ns) P value
(independently of themethod used to estimate it, seeMaterials
andMethods and Fig. 6B), leading us to exclude its relevance in
this mechanism. Instead, when we looked for putative TFAP2-
binding sites in pre-miR-148b–flanking regions, many low- and
3 high-affinity sites were found, including one located 1,816
nucleotides upstream of the pre-miR-148b, having 83% of the
maximum PWM score, with a potential role in controlling its
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transcription (Fig. 6A and C, top). Importantly, as indicated
in Fig. 6C, bottom, aChIP-seq analysis previously conducted on
HeLa cells [The ENCODE Project (29), SYDH-TFBS track],
revealed TFAP2A and TFAP2C binding in correspondence of
this binding site. In line with this, we carried out ChIP experi-
ments in MA-2 cells, as described earlier, and confirmed
TFAP2A/C-binding enrichment (1.9-fold) in this region (Fig.
6D), compared with IgG-negative control. These results sug-
gest that the miR-214 regulation on miR-148b is at least
partially due to TFAP2-mediated control on miR-148b. Indeed,
also miR-148b primary transcript (pri-miR-148b) evaluated by
qRT-PCR, was about 30% reduced in miR-214 (pre-miR-214)
overexpressing MA-2 cells (Fig. 6E) and, consistently, both
pri- (Fig. 6F and G) and mature (Fig. 6H and I) miR-148b
levels were more than 50% increased following overexpres-
sion of TFAP2A and TFAP2C. Taken together, our data
indicate that TFAP2A has a dual role on ALCAM regulation,
as summarized in Fig. 6J: it binds on ALCAM promoter and
represses ALCAM transcription; it controls ALCAM-target-
ing miR-148b expression.
miR-148b opposes miR-214–mediated prometastatic
functions in melanoma
Because we observed that ALCAM upregulation by miR-214
is at least in part due to miR-148b reduction, we explored the
functions of miR-148b in melanoma cell movement. miR-148b
was transiently overexpressed in MA-2 and WK-Mel cells by
pre-miR-148b transfection and cell migration was evaluated by
Transwell assays. Significantly, miR-148b overexpression led to
decreased cell movement compared with pre-control (Fig. 7A
Figure 5. miR-148b directly targets ALCAM and is downregulated by miR-214 in melanoma. A–E, ALCAM protein (A–D) and mRNA (E) expression levels were
evaluated by Western blot (A–D) or qRT-PCR (E) analyses, respectively, 48 to 72 hours following transient transfection of MA-2 (A), WK-Mel (B), SK-Mel-28
cells (C), or of miR-214–overexpressing MA-2 cells (pLemiR-214; D and E) with miR-214 and/or miR-148b precursors or negative controls (pre-miR-214 or
-148b or -control). Protein modulations were calculated relative to controls, normalized on hsp90 or GAPDH loading controls, and expressed as
percentages; mRNA modulations were calculated as fold changes (mean  SD of triplicates) relative to controls, normalized on 18S RNA level. F, scheme
showing WT or mutated (ALCAMmut) or deleted (ALCAMdel) miR-148b–binding site in human ALCAM 30-UTR (at position 273), paired with miR-148b seed.
The portion of ALCAM 30-UTR cloned in pMIR luciferase reporter vector is up to nucleotide 605, starting from the stop codon. G, luciferase assays in
MA-2 cells cotransfected with reporter constructs containing WT (ALCAM30-UTR) or mutant (ALCAMmut and ALCAMdel) ALCAM 30-UTRs or a synthetic
sequence including 3 perfect miR-148b–binding sites (miR-148b-sensor), cloned downstream of the luciferase coding sequence, together with
miR-148b precursors or negative controls (pre-miR-148b or -control). Results are shown as mean  SD of Firefly luciferase activity relative to controls,
normalized on Renilla luciferase activity. H–M, miR-148b (H–L) and miR-31 (M) expression levels were tested by qRT-PCR in MA-2 (H, I, and M), WK-Mel (J),
SK-Mel-28 (K), or MC-1 (L) cells following transfection with miR-214 precursors (H, K, and M; 72 hours posttransfection) or inhibitors (L; 24 hours
posttransfection) or their negative controls (pre- or anti-miR-214 or -control), or transduction with pLemiR-empty or miR-214 overexpression (pLemiR-214)
vectors (I and J). Results were calculated as fold changes (mean  SD of triplicates) relative to controls, normalized on U6 RNA level. Two or 3 independent
experiments were carried out in triplicate for E–M and representative results are shown.
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and B). Consistently, miR-148b silencing by anti-miR-148b
(Supplementary Fig. S1F) resulted in increased cell migration,
compared with anti-control–transfected cells (Fig. 7C). More
importantly, as shown in Fig. 7D, the concomitant overexpres-
sion of miR-148b in miR-214–overexpressing MA-2 cells (pLe-
miR-214þpre-miR-148b) was able to rescue miR-214–induced
increased cell migration (pLemiR-214þpre-control) similarly
to control cells (pLemiR-emptyþpre-control). We also
observed that survival to anoikis was decreased (Supplemen-
tary Fig. S3G). We then tested transendothelial migration, as
described earlier, and we observed decreased ability of MA-2
cells to migrate through the HUVECs-GFP monolayer when
miR-148b was overexpressed (pre-miR-148b) compared with
pre-control, opposite to pre-miR-214–transfected cells (Fig.
7E). Remarkably, concomitant miR-148b and miR-214 over-
expression (pre-miR-214þpre-miR-148b) completely rescued
miR-214–mediated transendothelial migration (Fig. 7E). When
we evaluated early lung colonization in vivo, 48 hours after tail
vein injection of MA-2 cells in nude mice, while miR-214
overexpression (pre-miR-214) significantly enhanced extrava-
sation, miR-148b overexpression alone (pre-miR-148b) mod-
erately reduced it, in comparison with pre-control transfected
cells, as shown in Fig. 7F. More importantly, when miR-148b
was upregulated in miR-214–overexpressing cells (pre-miR-
214þpre-miR-148b), we observed a rescuing of miR-214–
induced cell extravasation and early lung colonization (Fig.
7F), suggesting a role for miR-148b in miR-214/ALCAM–medi-
ated melanoma cell metastatic dissemination.
In conclusion, miR-148b is downregulated by miR-214, at
least in part via a TFAP2-driven mechanism, and these 2 small
RNAs exert opposite roles in melanoma cell dissemination, by
controlling ALCAM expression. These observations are
strengthened by the analysis of miR-214, miR-148b, ALCAM,
and TFAP2 in human patients with melanoma. We took
Figure 6. miR-148b downregulation by miR-214 is partially due to a TFAP2-mediated control. A, scheme showing the human pre-miR-148b locus
(chromosome 12, intron 1 of COPZ1 protein-coding gene) and the predicted interactions with miR-214 and TFAP2 as shown in B and C. B,
referring to A, predicted interaction of miR-214 on the pre-miR-148b locus (650 nucleotides downstream of pre-miR-148b), as obtained with the RNAHybrid
algorithm. MFE, minimum free energy (DG) predicted for hybridization; the P values were estimated on different backgrounds and are nonstatistically
significant (ns). C, referring to A, high affinity (black rectangles; score >80%of themaximum) and low affinity (gray rectangles; score between 60%and 80%of
the maximum) TFAP2-binding sites (BS) were obtained by the PWMmethod (top). The ENCODE Project SYDH-TFBS ChIP-seq analysis conducted on HeLa
cells shows TFAP2A and TFAPC but not immunoglobulin M (IgM; negative control) enrichment picks in pre-miR-148b flanking regions, for some putative
TFAP2 BS (bottom). D, ChIP. MA-2 cross-linked sheared chromatin was immunoprecipitated with either negative control (IgG) or anti-TFAP2 antibodies and
the TFAP2-binding site–containing miR-148b upstream region was PCR-amplified. TFAP2-binding enrichment was calculated relative to IgG-negative
control. E–I, miR-148b primary transcript (pri-miR-148b; E–G) and mature miR-148b (H and I) expression levels were tested by qRT-PCR in MA-2 cells
72 hours following transfection withmiR-214 precursors or negative controls (pre-miR-214 or -control) or with pSP(RSV)-empty or pSP(RSV)-TFAP2A or pSP
(RSV)-TFAP2C expression vectors. Results were calculated as fold changes (mean  SD of triplicates) relative to controls, normalized on 18S or
U6 RNA level. At least 2 independent experiments were carried out in triplicate for E–I and are shown either as representative results (D, F–I) or as themean
SEM of 7 independent experiments (E). J, our data show that ALCAM is overexpressed in melanoma because miR-214 downregulates both TFAP2A/C
(ALCAM transcriptional repressors) and miR-148b (ALCAM-targeting miR). Relevantly, TFAP2A/C positively regulate miR-148b expression.
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advantage of the same cohort of patients used in (18, 30). As
indicated in Fig. 7G, bottom, we previously showed that miR-
214 was significantly more expressed, whereas TFAP2A and
TFAP2C were less expressed, in invasive melanoma samples
compared with noninvasive (in situ) ones, by qRT-PCR and
immunoistochemical analyses, respectively (18, 30). In a
Figure 7. miR-148b opposesmiR-214 prometastatic functions inmelanoma. A–E, Transwell migration through a poremembrane (A–D) or a fibronectin-coated
membrane covered by a confluent monolayer of HUVECs-GFP (E; bar, 50 mm) was evaluated following transient transfection with miR-214 and/or
miR-148b precursors or inhibitors or their negative controls (pre-miR-214 or -148b or anti-miR-148b or -control) of MA-2 (A, C, and E; CMRA-labeled in E) or
WK-Mel (B) cells or of miR-214–overexpressing MA-2 cells (pLemiR-214; D). F, in vivo extravasation assay 48 hours following tail vein injections
in nudemice of CMRA-labeledMA-2 cells transfected as in E. Representative pictures of whole lungs are presented (a–d; bar, 800 mm). Results are shown as
mean  SEM of the area covered by migrated cells or of the number of extravasated cells in the lungs, for n ¼ 5 mice per group. Two or 3
independent experiments were carried out (in triplicate for A–E) and representative results are shown. G, ALCAMmRNA levels (top) and miR-148b/miR-214
expression ratio (middle) were evaluated in a cohort of n ¼ 6 in situ versus n ¼ 16 invasive human melanomas. Relative protein-coding gene or miR
expression was obtained by qRT-PCR analyses, calculated using the median as reference, and normalized on GAPDH or U44 RNA levels, respectively. The
horizontal line (top) represents the mean for the in situ melanomas. The Mann–Whitney nonparametric test was used for the statistical analysis of
ALCAMexpression. TFAP2A, TFAP2C, andmiR-214 expression levels represented by gray scales (bottom) refer to our previously publishedworks (indicated)
and were obtained by immunoistochemical and qRT-PCR analyses, respectively.
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subgroup of the same samples, we now evaluated ALCAM
mRNA expression by qRT-PCR and found a significant
increase in invasive melanomas (n ¼ 16) compared with
in situ tumors (n ¼ 6; Fig. 7G, top), thus reinforcing
our findings. Importantly, when we considered miR-148b/
miR-214 expression ratio by qRT-PCR in this cohort (Fig. 7G,
middle) and in a new independent cohort of patients with
melanoma (n ¼ 10 in situ and n ¼ 10 invasive; Supplemen-
tary Fig. S4, top), we consistently found low miR-148b (less
than 10%) and high miR-214 relative levels, indicating that
miR-148b is maintained low in high miR-214–expressing
melanomas, at least partially by the earlier described
miR-214–mediated mechanism.
Discussion
We previously showed a prometastatic function for miR-214
in melanoma (18). The present work spotted light on the
link between miR-214 and ALCAM in the coordination of
melanomaprogression. Here, we show that ALCAMexpression
increases when miR-214 is upregulated in several different
melanoma cell lines, independently of BRAFV600E mutation
status. Previously, we found increased levels of miR-214 in
metastatic melanoma cells compared with their poorly malig-
nant counterparts and in invasive or metastatic human
melanomas but not in in situ samples (18). Supporting the
connection between miR-214 and ALCAM are the immuno-
histochemical analyses for ALCAM in human melanoma sam-
ples, which show a perfect correlation between higher levels of
ALCAM and thicker lesions or later tumor stages, from com-
monnevi tometastases (8). ALCAMexpressionwas specifically
detected at the invasive front ofmelanomas (8).Moreover, here
we highlighted increased ALCAMmRNAexpression in invasive
high miR-214–expressing human melanomas, compared with
in situ lesions. In addition, ALCAM resulted to be highly
expressed in xenotransplants and metastases originated in
mice following injection of melanoma cell variants with high
levels of miR-214 (17). Finally, ALCAM expression associates
with poor prognosis or relapse for other human tumors,
including colorectal, bladder, esophageal, and intraductal
breast carcinomas (7, 31, 32) and high ALCAM or miR-214
serum levels are considered poor prognostic markers for some
kind of neoplasia (33–36).
ALCAM has a key role in normal tissue or tumor integrity, in
heterotypic tumor cell–endothelial cell interactions and in
immune cell attachment and transmigration through vessels
(5, 6, 37), therefore it is fundamental for primary tumor mass
growth and tumor escaping. ALCAM connections are essential
for cell movement (9), for efficient conversion of pro-MMP-2 to
its active form in metastatic melanoma cells (11) and for the
retention of intravascular breast tumor cell clusters in the lung
vessels (38). Consistently, we showed that ALCAM overexpres-
sion promotes cell migration, whereas silencing blocks it in
different melanoma cell lines. More importantly, we proved
that miR-214 prometastatic functions are exerted via ALCAM,
at least in part. In fact, ALCAM silencing in miR-214–over-
espressing cells significantly reduces miR-214–mediated
increased cell movement, invasion, and transendothelial
migration in vitro and efficiently impairs extravasation and
metastatic dissemination in mice, both following direct
injection of melanoma cells in the blood circulation and
when we analyzed lung metastatic lesions spontaneously
originating from experimental tumors. Because these results
were obtained for 3 distinct melanoma cell lines, indepen-
dently of BRAFV600E mutation status, and for a breast cancer
cell line, we conclude that miR-214–mediated ALCAM upre-
gulation has a broad-spectrum key role in tumor cell met-
astatic dissemination.
Despite the clear correlation between ALCAM expression
and melanoma malignancy, the mechanisms leading to
ALCAM upregulation are still poorly understood. It is known
that ALCAM expression is regulated by promoter CpG islands
methylation (38) and by transcriptional regulation exerted by
NF-kB (38) and GATA1 (39) transcription factors. Here, we
propose that miR-214 regulates ALCAM indirectly via a tran-
scriptional and a posttranscriptional control. About the tran-
scriptional control, we postulate that miR-214 upregulates
ALCAM transcription by downregulating its targets TFAP2A
and TFAP2C. Loss of TFAP2 during melanoma progression is
well documented (40), and we showed here and previously (18)
that it is governed, at least in part, by miR-214, in different
melanoma cell lines.miR-214 directly targets TFAP2C,whereas
TFAP2A is indirectly downregulated, probably via TFAP2C.
Indeed, it is known that TFAP2C silencing reduces TFAP2A
protein levels (unpublished data) and that TFAP2 family
members regulate each other transcriptionally (41). Here, we
show that ALCAMmRNA and protein expression decreases in
TFAP2-overexpressing MA-2 or WK-Mel cells. Moreover, we
identified 5 putative TFAP2-binding sites on ALCAMpromoter
and proved TFAP2A/C-binding enrichment on this region, via
a ChIP experiment. Importantly, we observed a strong down-
regulation of luciferase expression when the activity of ALCAM
promoter was tested in cells overexpressing TFAP2 family
members, using a luciferase reporter. The deletion of each
single binding site or of combinations of them or of the entire
region encompassing the 5 sites suggests their cooperative
action. In fact, the ablation of multiple or all sites was able to
abrogate TFAP2-dependent luciferase activity reduction.
Decreased levels of ALCAM, comparable with low miR-214–
expressing cells, were seen in miR-214–overexpressing cells
following TFAP2A and, partially, TFAP2C reexpression, indi-
cating that the downmodulation of TFAP2 factors by miR-214,
occurring during metastatic dissemination, is necessary to
remove the direct transcriptional repression of TFAP2 on
ALCAM promoter. Importantly, we previously proved that
TFAP2C is responsible for many miR-214 prometastatic func-
tions and that TFAP2C reexpression in miR-214–overexpres-
sing cells was able to rescue miR-214–induced cell movement
and early lung metastatic colonization (18). Interestingly, this
TFAP2-mediated regulation is similar to what previously
shown for the ALCAM homolog MCAM-MUC-18 adhesion
molecule in melanoma (42).
About the posttranscriptional control, we showed that miR-
214 upregulates ALCAM expression by reducing another small
noncoding RNA, miR-148b, which was predicted to directly
target ALCAM. In agreement with bioinformatics anticipa-
tions, we observed significant downmodulation of ALCAM
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protein following miR-148b overexpression. Direct targeting
was proven by luciferase reporter assays on WT but not on
miR-148b seed-mutants. Importantly, we observed decreased
miR-148b levels following miR-214 overexpression in different
melanoma cell lines and, vice versa, increased levels in miR-
214–silenced cells. Significantly, miR-148b overexpression in
miR-214–overexpressing cells was able to reestablish low
ALCAM levels, as in control cells. Our results suggested a
miR-on-miR regulatory loop between miR-148b and miR-
214, in which miR-214 could control miR-148b transcription
or processing or stability. Another miR-on-miR regulation was
previously described for mouse miR-709, which binds on pri-
miR-15a/16-1 thus preventing its processing (28). By using the
same approach, we looked for possible miR-214 recognition
sites around miR-148b locus, but found only a nonstatistically
significant putative site, located downstream of pre-miR-148b.
Instead, the observation that also pri-miR-148b was down-
modulated following miR-214 overexpression and that many
putative TFAP2-binding sites were present in miR-148b locus,
including a high affinity one in the potential promoter region,
led us to investigate a possible transcriptional regulation. On
this line, we and others (The ENCODE project) proved TFAP2-
binding enrichment on this site by ChIP analyses. In addition,
pri- and mature miR-148b expression increased following
TFAP2A and TFAP2C overexpression. However, we cannot
exclude additional regulations, such as posttranscriptional
functions of TFAP2 or, as it is well known that miR-148/152
expression is controlled by promoter methylations (43), pos-
sible miR-214–controlled epigenetic mechanisms.
In conclusion, our data indicate thatmiR-214–driven TFAP2
downregulation occurring during melanomamalignancy, con-
trols ALCAM expression in a dual way: directly, at the tran-
scriptional level, as well as indirectly, by controlling the
expression of ALCAM-targeting miR-148b. These data are
further reinforced by ours and others observations showing
that ALCAM expression increases, whereas TFAP2 decreases
and that high levels of miR-214 anticorrelate with poor miR-
148b expression during melanoma progression, as assessed in
melanoma cell lines and tissues (18, 44). Relevantly, we recently
showed that miR-148b inhibits breast cancer progression,
mainly by affecting cell movement and survival (45). Similarly,
and opposite to what shown for miR-214 (18), miR-148b
considerably opposes melanoma cell movement, transen-
dothelial migration and, to a lesser extent, survival to anoikis.
More importantly, when miR-148b was upregulated in miR-
214–overexpressing cells, it was able to rescue miR-214/
ALCAM–mediated prometastatic effects on melanoma cell
movement and early lung metastatic colonization.
Taken together, our data indicate that miR-214–driven
ALCAM upregulation in metastatic melanoma cells depends
on transcriptional (mediated by TFAP2) and posttranscrip-
tional (mediated by miR-148b, itself controlled by TFAP2)
mechanisms. Furthermore, miR-214 and miR-148b, with their
direct targets, respectively TFAP2 and ALCAM, have opposite
effects onmelanoma tumor cell dissemination and are part of a
new regulatory loop that could be explored for therapeutic
attempts.
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